Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).

MLA

Joly, Florence, et al. “Improving Real-World Evaluation of Patient- and Physician-Reported Tolerability: Niraparib for Recurrent Ovarian Cancer (NiQoLe).” JNCI Cancer Spectrum, Dec. 2024. EBSCOhost, https://doi.org/10.1093/jncics/pkae114.

APA

Joly, F., Bazan, F., Garbay Decoopman, D., Ouldbey, Y., Follana, P., Champeaux-Orange, É., Legouffe, E., Brachet, P.-E., Spaeth, D., Combe, P., Hardy-Bessard, A.-C., Selle, F., Grenier, J., Lebreton, C., Derbel, O., Bonnet, E., Fournel, P., Fernandez Diez, Y., Delecroix, V., … Kurtz, J.-E. (2024). Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe). JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae114

Chicago

Joly, Florence, Fernando Bazan, Delphine Garbay Decoopman, Yaelle Ouldbey, Philippe Follana, Élise Champeaux-Orange, Eric Legouffe, et al. 2024. “Improving Real-World Evaluation of Patient- and Physician-Reported Tolerability: Niraparib for Recurrent Ovarian Cancer (NiQoLe).” JNCI Cancer Spectrum, December. doi:10.1093/jncics/pkae114.